

Pituitary Suppressive Agents - LHRH

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Patient Name:		Prescriber Name:	
HPP HPP Member Number:		Fax:	Phone:
Date of Birth:		Office Contact:	
Patient Primary Phone:		NPI:	PA PROMISe ID:
Address:		Address:	
City, State ZIP:		City, State ZIP:	
Line of Business: <input type="checkbox"/> Medicaid <input type="checkbox"/> CHIP		Specialty Pharmacy (if applicable):	
Drug Name:		Strength:	
Quantity:		Refills:	
Directions:			
Diagnosis Code:		Diagnosis:	
<i>HPP's maximum approval time is 12 months but may be less depending on the drug.</i>			

Please attach any pertinent medical history including labs and information for this member that may support approval.

Please answer the following questions and sign.

Q1. Is the requested drug for an indication that is included in the United States (U.S.) Food and Drug Administration (FDA)-approved package labeling OR a medically accepted indication?

Yes

No

Q2. Is the requested drug prescribed at a dose and duration of therapy that is consistent with the Food and Drug Administration (FDA)-approved package labeling, nationally recognized compendia, or peer-reviewed medical literature?

Yes

No

Q3. Does the patient have a history of a contraindication to the prescribed medication?

Yes

No

Q4. Is the patient age-appropriate for the requested drug according to the Food and Drug Administration (FDA) approved package labeling, nationally recognized compendia, or peer-reviewed medical literature?

Yes

No

Q5. For diagnosis of central precocious puberty, the medication prescribed by or in consultation with a pediatric endocrinologist?

Pituitary Suppressive Agents - LHRH

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Patient Name:	Prescriber Name:
<input type="checkbox"/> Yes	<input type="checkbox"/> No
Q6. For a diagnosis of central precocious puberty, is the patient <11 years of age for females or <12 years of age for males?	
<input type="checkbox"/> Yes	<input type="checkbox"/> No
Q7. For a diagnosis of central precocious puberty, has the patient developed the onset of secondary sexual characteristics earlier than 8 years of age in females and 9 years of age in males?	
<input type="checkbox"/> Yes	<input type="checkbox"/> No
Q8. Does the patient have a diagnosis of gender dysphoria?	
<input type="checkbox"/> Yes	<input type="checkbox"/> No
Q9. Is the patient an adolescent?	
<input type="checkbox"/> Yes	<input type="checkbox"/> No
Q10. Is the requested drug prescribed by or in consultation with a pediatric endocrinologist, adolescent medicine specialist, or medical provider with experience and/or training in transgender medicine?	
<input type="checkbox"/> Yes	<input type="checkbox"/> No
Q11. Is the requested drug prescribed in a manner consistent with the current World Professional Association for Transgender Health standards of care for the health of transsexual, transgender, and gender nonconforming people?	
<input type="checkbox"/> Yes	<input type="checkbox"/> No
Q12. Is the patient an adult?	
<input type="checkbox"/> Yes	<input type="checkbox"/> No
Q13. Is the requested drug prescribed by or in consultation with an endocrinologist or medical provider with experience and/or training in transgender medicine?	

Pituitary Suppressive Agents - LHRH

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Patient Name:	Prescriber Name:
<input type="checkbox"/> Yes	<input type="checkbox"/> No
Q14. Is the requested drug prescribed in a manner consistent with the current World Professional Association for Transgender Health standards of care for the health of transgender and gender diverse people?	
<input type="checkbox"/> Yes	<input type="checkbox"/> No
Q15. Does the patient have a diagnosis of endometriosis?	
<input type="checkbox"/> Yes	<input type="checkbox"/> No
Q16. Is the diagnosis of endometriosis confirmed by laparoscopy OR supported by chart documentation of an adequate work-up that includes the clinical rationale for the diagnosis?	
<input type="checkbox"/> Yes	<input type="checkbox"/> No
Q17. Does the patient have a history of therapeutic failure, contraindication, or intolerance to non-steroidal anti-inflammatory drugs (NSAIDs), AND therapeutic failure (based on a 3-month trial), contraindication, or intolerance to oral contraceptives?	
<input type="checkbox"/> Yes	<input type="checkbox"/> No
Q18. Is the requested drug prescribed by or in consultation with a gynecologist?	
<input type="checkbox"/> Yes	<input type="checkbox"/> No
Q19. Is the requested drug being used for the preservation of ovarian function?	
<input type="checkbox"/> Yes	<input type="checkbox"/> No
Q20. Is the patient receiving cancer treatment that is associated with premature ovarian failure (based on NCCN guidelines or peer-reviewed medical literature)?	
<input type="checkbox"/> Yes	<input type="checkbox"/> No
Q21. Is the requested drug Oriahnn (elagolix, estradiol, norethindrone, elagolix) or Myfembree (relugolix/estradiol/norethindrone)?	
<input type="checkbox"/> Yes	<input type="checkbox"/> No

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document

Pituitary Suppressive Agents - LHRH

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Patient Name:	Prescriber Name:
---------------	------------------

Q22. Is Oriahnn (elagolix, estradiol, norethindrone, elagolix) or Myfembree (relugolix/estradiol/norethindrone) being used for the management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in a premenopausal woman?

Yes No

Q23. Does the patient have a history of therapeutic failure (based on a 3-month trial), contraindication, or intolerance of contraceptives?

Yes No

Q24. Does the patient have a history of depression and/or suicidal thoughts or behaviors or is currently receiving treatment for depression and/or suicidal thoughts or behavior?

Yes No

Q25. Has a behavioral health assessment been performed prior to use of Oriahnn (elagolix, estradiol, norethindrone, elagolix) or Myfembree (relugolix/estradiol/norethindrone)?

Yes No

Q26. Is the requested drug a non-preferred agent?

Yes No

Q27. Does the patient have a history of therapeutic failure, contraindication, or intolerance to the preferred Pituitary Suppressive Agents, LHRH approved or medically accepted for the patient's indication?

Yes No

Q28. Additional Information:

Prescriber Signature

Date

Updated for 2024

Pituitary Suppressive Agents - LHRH

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Patient Name:	Prescriber Name:
---------------	------------------